Yes , great link from RMB . Re P values etc ...thx but Laurent for the old AMRN board is my go to guy for P values , stopping boundaries etc Re the ICU Pediatric and adult trials . In pediatric its over 90% survival on max ICU care plus vasoactive meds ( makes the heart pump better ) and even some mechanical ventilation . ECMO is added as a last resort ...only if all else fails . So the more they use the SCD filter , the more they learn, and are ( my guess ) likely to intervene earlier and reduce risk of needing ECMO ...which would increase over all survival rates .
The problem for ICU is getting the Adult trial fully enrolled before they burn thru their cash agin ...chk the one yr chart ...90% loss of your investment is you had been in this for the past yr.
As opposed to UNCY ..all trials finished . No problem with clinical data . 100% Medicare reimbursed once in TDAPA etc
One thing I should add about ICU ...I THINK the last capital raise was largely institutional buying ...can anyone confirm Kiwi
Market Data 
Markets 
AI
